Opportunity Information: Apply for PA 07 273
Apply for PA 07 273
- The National Institutes of Health in the education environment health income security and social services sector is offering a public funding opportunity titled "Understanding and Treating Ataxia Telangiectasia (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.172 Human Genome Research 93.173 Research Related to Deafness and Communication Disorders 93.396 Cancer Biology Research 93.838 Lung Diseases Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.865 Child Health and Human Development Extramural Research 93.866 Aging Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Jan 4, 2007.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: For profit organizations other than small businesses Native American tribal governments (Federally recognized) Independent school districts City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) State governments County governments.
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Understanding and Treating Ataxia Telangiectasia (R21) funding opportunity (PA 07 273) is a National Institutes of Health (NIH) grant program designed to spark new, exploratory research focused on Ataxia Telangiectasia (A T). Multiple NIH institutes are participating, led by interests spanning neurology, cancer biology, cardiovascular and lung issues, genomics, aging, child health and development, communication disorders, and environmental health (including NINDS, NCI, NHLBI, NHGRI, NIA, NICHD, NIDCD, and NIEHS). The program is also supported in collaboration with two patient-focused nonprofit partners, the Ataxia Telangiectasia Childrens Project and the A T Ease Foundation. The overall intent is to bring more scientific attention and momentum to A T by encouraging creative, interdisciplinary ideas that can clarify disease mechanisms and move potential treatments closer to reality.
At its core, the opportunity is aimed at projects that improve understanding of how A T symptoms arise and progress, while also accelerating paths toward therapies. The announcement explicitly welcomes a wide range of research stages, including basic science (for example, work on underlying biology and pathways), translational research (bridging lab findings toward practical interventions), and clinical studies (involving patients, clinical endpoints, or early-stage testing strategies). In addition to hypothesis-driven studies, the FOA emphasizes the development of resources that can make future A T research faster and more effective, such as shared tools, datasets, model systems, or other enabling platforms. Another major goal is to stimulate progress by encouraging and facilitating interdisciplinary interaction, reflecting the reality that A T touches many organ systems and scientific domains.
The grant mechanism used here is the NIH Exploratory/Developmental Research Grant (R21). That choice matters because R21s are typically intended for early-stage, high-impact ideas that may still be building preliminary data. In other words, the program is positioned to support novel approaches, pilot studies, proof-of-concept work, or the kind of targeted development that can set up larger projects later. This FOA runs in parallel with two companion announcements covering the same scientific scope but using different grant types: an R01 (PA 07 272) for more mature, full-scale research projects, and an R03 (PA 07 274) for small research grants. Applicants are expected to choose the mechanism that best matches the size, readiness, and goals of their proposed work.
The budget and timeline are tightly defined in typical R21 fashion. Projects can last up to two years total, and the R21 under this announcement is not renewable. Direct costs are capped at 275,000 total across the two-year period, with an additional constraint that no single year may exceed 200,000 in direct costs. Awards depend on the availability of funds and on the submission of enough high-quality applications, so there is no guaranteed number of awards or fixed total funding level spelled out. The agency notes that award size and duration can vary by project, which is a way of recognizing that exploratory A T studies may differ substantially in methods and cost structure.
Eligibility is broad and intentionally inclusive. A wide spectrum of organizations can apply, including public and private institutions of higher education, nonprofits both with and without 501(c)(3) status, small businesses, for-profit organizations (including those beyond small businesses), state and local governments, U.S. territories, tribal governments and tribally designated organizations, and other regional entities. The announcement also makes clear that foreign (non-U.S.) organizations are eligible, as are eligible federal agencies, and faith-based or community-based organizations. It also explicitly includes eligibility categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions, signaling an effort to keep the applicant pool diverse and wide-reaching. There is no cost-sharing or matching requirement.
Administratively, the opportunity is listed as a discretionary grant under NIH, with multiple receipt dates rather than a single deadline (the specific dates are referenced in the full announcement). The posting history indicates the opportunity was originally posted January 4, 2007, and later archived February 2, 2010, meaning it was active during that period and applicants would have followed the NIH receipt cycles then in place. The associated CFDA numbers span multiple NIH research areas (including neuroscience and neurological disorders, cancer biology, lung diseases, aging, child health and development, deafness and communication disorders, human genome research, and environmental health), which reflects how the participating institutes are pooling interest around A T.
Taken together, this FOA is best understood as a short-term, high-leverage funding lane for researchers who want to test bold ideas, build enabling tools, or push early therapeutic concepts forward in Ataxia Telangiectasia, with the added emphasis that progress is likely to come from cross-disciplinary teams and approaches rather than from a single field working in isolation.
Frequently Asked Questions (FAQs): Understanding and Treating Ataxia Telangiectasia (R21) - PA 07-273
What is the "Understanding and Treating Ataxia Telangiectasia (R21)" funding opportunity?
It is a National Institutes of Health (NIH) funding opportunity announcement (FOA) designed to stimulate new, exploratory research focused on Ataxia Telangiectasia (A-T). The specific mechanism is the NIH Exploratory/Developmental Research Grant (R21), and the FOA identifier is PA 07-273.
What is the main purpose of this R21 program?
The intent is to bring additional scientific attention and momentum to A-T by encouraging creative, interdisciplinary research that improves understanding of disease mechanisms and helps move potential treatments closer to reality.
What types of research does this FOA support?
The announcement welcomes a broad range of research stages, including basic science, translational research, and clinical studies. It also emphasizes work that can clarify how A-T symptoms arise and progress while accelerating paths toward therapies.
Are clinical studies allowed under this FOA?
Yes. The scope explicitly includes clinical studies, including work involving patients, clinical endpoints, or early-stage testing strategies, as described in the opportunity summary.
Does the FOA require projects to be hypothesis-driven?
No. In addition to hypothesis-driven studies, the FOA emphasizes development of resources that can speed and strengthen future A-T research (for example, shared tools, datasets, and model systems).
What does "interdisciplinary" mean in the context of this opportunity?
The FOA encourages cross-disciplinary interaction because A-T involves many organ systems and scientific domains. It is positioned to support approaches that draw on multiple fields rather than staying within a single discipline.
Which NIH institutes and centers are involved?
Multiple NIH components participate, spanning interests in neurology, cancer biology, cardiovascular and lung issues, genomics, aging, child health and development, communication disorders, and environmental health. The participating groups named include NINDS, NCI, NHLBI, NHGRI, NIA, NICHD, NIDCD, and NIEHS.
Are any non-NIH partners involved?
Yes. The program is supported in collaboration with two patient-focused nonprofit partners: the Ataxia Telangiectasia Childrens Project and the A-T Ease Foundation.
What grant mechanism is used and why does it matter?
This FOA uses the NIH R21 mechanism (Exploratory/Developmental Research Grant). R21s are typically intended for early-stage, potentially high-impact ideas that may still be building preliminary data, such as pilot studies, proof-of-concept work, novel approaches, or targeted development that can enable larger projects later.
How is this R21 related to other A-T funding announcements?
This FOA runs in parallel with companion announcements covering the same scientific scope but using different mechanisms: an R01 (PA 07-272) for more mature, full-scale research projects, and an R03 (PA 07-274) for small research grants. Applicants are expected to choose the mechanism that fits their project size and readiness.
What is the maximum project period?
The project period can be up to two years total.
Is this R21 renewable?
No. Under this announcement, the R21 is not renewable.
What is the budget limit for this R21?
Direct costs are capped at $275,000 total over the two-year period, with an additional constraint that no single year may exceed $200,000 in direct costs.
Does the FOA guarantee a certain number of awards or a fixed funding level?
No. Awards depend on the availability of funds and the submission of a sufficient number of meritorious applications. The opportunity description does not specify a guaranteed number of awards or a fixed total funding amount.
Can award size and duration vary across projects?
Yes. The agency notes that award size and duration can vary by project, recognizing that exploratory A-T studies may differ in methods and cost structure (within the stated R21 limits and maximum project period).
Who is eligible to apply?
Eligibility is broad. Applicants may include public and private institutions of higher education; nonprofits with or without 501(c)(3) status; small businesses; for-profit organizations (including those beyond small businesses); state and local governments; U.S. territories; tribal governments and tribally designated organizations; and other regional entities.
Are foreign (non-U.S.) organizations eligible?
Yes. The announcement explicitly states that foreign organizations are eligible.
Are federal agencies eligible to apply?
Yes. Eligible federal agencies are explicitly included in the eligibility description.
Are faith-based or community-based organizations eligible?
Yes. The eligibility language explicitly includes faith-based and community-based organizations.
Does the FOA encourage applications from specific institution types?
The announcement explicitly includes categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and Alaska Native and Native Hawaiian serving institutions, signaling an intent to keep the applicant pool diverse and wide-reaching.
Is cost-sharing or matching required?
No. The opportunity states there is no cost-sharing or matching requirement.
Are there multiple deadlines or a single deadline?
The opportunity indicates multiple receipt dates rather than a single deadline, with specific dates referenced in the full announcement.
When was this FOA posted and when was it archived?
The posting history states it was originally posted on January 4, 2007, and later archived on February 2, 2010, meaning it was active during that period.
What CFDA program areas does this opportunity touch?
The CFDA numbers span multiple NIH research areas, reflecting the participating institutes' interests. The listed areas include neuroscience and neurological disorders, cancer biology, lung diseases, aging, child health and development, deafness and communication disorders, human genome research, and environmental health.
How should an applicant decide between the R21, R01, and R03 options mentioned?
Based on the description provided, the R21 is positioned for early-stage, exploratory or developmental efforts with tight timelines and budget caps; the companion R01 targets more mature, full-scale projects; and the companion R03 targets small research grants. Applicants are expected to select the mechanism that best matches their project scope, readiness, and goals.
What kinds of enabling resources does the FOA encourage?
It emphasizes resource development that can make future A-T research faster and more effective, such as shared tools, datasets, model systems, or other enabling platforms.
Is the program limited to one scientific area within A-T?
No. The participating NIH institutes reflect a wide scientific footprint (neurology, cancer biology, cardiovascular and lung issues, genomics, aging, child development, communication disorders, and environmental health), consistent with A-T affecting multiple organ systems.
What is the overall "best fit" for this FOA based on the description?
It is best understood as a short-term, high-leverage funding path for researchers who want to test bold ideas, build enabling tools, or push early therapeutic concepts forward in A-T, with a clear emphasis on interdisciplinary approaches.
Browse more opportunities from the same category: Education Environment Health Income Security and Social Services
Next opportunity: Understanding and Treating Ataxia Telangiectasia (R03)
Previous opportunity: Understanding and Treating Ataxia Telangiectasia (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 07 273
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 07 273) also looked into and applied for these:
| Funding Opportunity |
|---|
| Understanding and Treating Ataxia Telangiectasia (R03) Apply for PA 07 274 Funding Number: PA 07 274 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $50,000 |
| Bioengineering Research Grants (BRG)(R01) Apply for PA 07 279 Funding Number: PA 07 279 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Novel Approaches to Enhance Animal Stem Cell Research (R01) Apply for PA 07 303 Funding Number: PA 07 303 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Novel Approaches to Enhance Animal Stem Cell Research (R21) Apply for PA 07 304 Funding Number: PA 07 304 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Bioengineering Research Partnerships (BRP)R01 Apply for PAR 07 352 Funding Number: PAR 07 352 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $2,000,000 |
| Behavioral and Social Science Research on Understanding and Reducing Health Disparities (R21) Apply for PAR 07 380 Funding Number: PAR 07 380 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Advancing Novel Science in Women s Health Research (ANSWHR) R21 Apply for PAS 07 381 Funding Number: PAS 07 381 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $2,000,000 |
| Advancing Novel Science in Women s Health Research (ANSWHR) (R03) Apply for PAS 07 382 Funding Number: PAS 07 382 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Understanding and Treating Generalized and Focal Dystonias (R01) Apply for PA 07 397 Funding Number: PA 07 397 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Understanding and Treating Generalized and Focal Dystonias (R21) Apply for PA 07 398 Funding Number: PA 07 398 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Developmental Pharmacology (R01) Apply for PAR 07 416 Funding Number: PAR 07 416 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Neuroimaging Informatics Software Enhancement for Improved Interoperability and Dissemination (R03) Apply for PAR 07 417 Funding Number: PAR 07 417 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Data Ontologies for Biomedical Research (R01) Apply for PAR 07 425 Funding Number: PAR 07 425 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| ELSI Regular Research Program (R01) Apply for PA 08 012 Funding Number: PA 08 012 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| ELSI Small Research Grant Program (R03) Apply for PA 08 013 Funding Number: PA 08 013 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Community Participation in Research (R01) Apply for PA 08 074 Funding Number: PA 08 074 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Brain Disorders in the Developing World Research Across the Lifespan (R01) Apply for PAR 08 112 Funding Number: PAR 08 112 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Brain Disorders in the Developing World Research Across the Lifespan (R21) Apply for PAR 08 113 Funding Number: PAR 08 113 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Genetic Screens to Enhance Zebrafish Research (R01) Apply for PAR 08 138 Funding Number: PAR 08 138 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Methodology and Measurement in the Behavioral and Social Sciences (R01) Apply for PAR 08 212 Funding Number: PAR 08 212 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 273", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.